Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Davidson

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Prevalence of pulmonary embolism among patients with recent onset of dyspnea on exertion. A cross-sectional studyPaolo Prandoni, Anthonie W A Lensing, Martin H Prins, et al.
The New England Journal of Medicine|December 7, 2010
Oral rivaroxaban for symptomatic venous thromboembolism, Rupert Bauersachs, Scott D Berkowitz, et al.
Thrombosis Research|August 2, 2018
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirinPaolo Prandoni, Anthonie W A Lensing, Martin H Prins, et al.
The New England Journal of Medicine|March 28, 2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, Harry R Büller, Martin H Prins, et al.
Blood Advances|April 11, 2018
Risk of recurrent venous thromboembolism according to baseline risk factor profilesMartin H Prins, Anthonie W A Lensing, Paolo Prandoni, et al.
The New England Journal of Medicine|March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismJeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Prevalence of pulmonary embolism among patients with recent onset of dyspnea on exertion. A cross-sectional studyPaolo Prandoni, Anthonie W A Lensing, Martin H Prins, et al.
The New England Journal of Medicine|December 7, 2010
Oral rivaroxaban for symptomatic venous thromboembolism, Rupert Bauersachs, Scott D Berkowitz, et al.
Thrombosis Research|August 2, 2018
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirinPaolo Prandoni, Anthonie W A Lensing, Martin H Prins, et al.
The New England Journal of Medicine|March 28, 2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, Harry R Büller, Martin H Prins, et al.
Blood Advances|April 11, 2018
Risk of recurrent venous thromboembolism according to baseline risk factor profilesMartin H Prins, Anthonie W A Lensing, Paolo Prandoni, et al.
The New England Journal of Medicine|March 21, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismJeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, et al.
Pageof 8